Phase III HELP study of Takhzyro shows long-term safety and efficacy in Hereditary Angioedema – Takeda
Takeda Pharmaceutical announced results from two final analyses from the Phase III HELP (Hereditary Angioedema Long-term Prophylaxis) Study Open-label Extension (OLE), which evaluated the long-term safety (primary endpoint)… read more.